Optimer Looking At Prophylaxis As Next Frontier For C. Difficile Agent Dificid

Optimer's next step, having garnered the expected FDA approval of its Clostridium difficile antibiotic Dificid (fidaxomicin), will be to consider prophylaxis as a possible road to an expanded market for the macrolide antibiotic.